ReviewInternational journal of molecular sciences2015
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability.Journal of materials science. Materials in medicine · 2026Review
- Chitosan-coated mesoporous silica nanoparticles for pH-responsive doxorubicin delivery in head and neck cancer.Frontiers in bioengineering and biotechnology · 2026Article
- Expanding the horizons of targeted protein degradation: A non-small molecule perspective.Acta pharmaceutica Sinica. B · 2024Review
- Theranostic Fluorescent Probes.Chemical reviews · 2024Review
- Current Status of Oligonucleotide-Based Protein Degraders.Pharmaceutics · 2023Review
- Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin.Molecular therapy. Nucleic acids · 2022Article
- Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme.Membranes · 2022Article
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One.Journal of medicinal chemistry · 2022Review
- Review
- Functionalized monolithic columns: Recent advancements and their applications for high-efficiency separation and enrichment in food and medicine.Frontiers in chemistry · 2022Review
- Aptamers: Cutting edge of cancer therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3.Cancer biology & therapy · 2021Article
- Aptamers: An Emerging Tool for Diagnosis and Therapeutics in Tuberculosis.Frontiers in cellular and infection microbiology · 2021Review
- Synthesis and Application of AS1411-Functionalized Gold Nanoparticles for Targeted Therapy of Gastric Cancer.ACS omega · 2020Article
- In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells.Nature communications · 2020Article
- Therapeutic applications of nucleic acid aptamers in microbial infections.Journal of biomedical science · 2020Review
- Opportunities and challenges in the nanoparticles for nucleic acid therapeutics: the first approval of an RNAi nanoparticle for treatment of a rare disease.National science review · 2019Article
- A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.International journal of nanomedicine · 2019Article
- Simultaneous Monitoring of Cell-surface Receptor and Tumor-targeted Photodynamic Therapy via TdT-initiated Poly-G-Quadruplexes.Scientific reports · 2018Article
- NDRG2 suppression as a molecular hallmark of photoreceptor-specific cell death in the mouse retina.Cell death discovery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamers, which can be screened via systematic evolution of ligands by exponential enrichment (SELEX), are superior ligands for molecular recognition due to their high selectivity and affinity. The interest in the use of aptamers as ligands for targeted drug delivery has been increasing due to their unique advantages. Based on their different compositions and preparation methods, aptamer-functionalized targeted drug delivery systems can be divided into two main categories: aptamer-small molecule conjugated systems and aptamer-nanomaterial conjugated systems. In this review, we not only summarize recent progress in aptamer selection and the application of aptamers in these targeted drug delivery systems but also discuss the advantages, challenges and new perspectives associated with these delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.